Octavia Wealth Advisors LLC Has $428,000 Holdings in Eli Lilly and Company (NYSE:LLY)

Octavia Wealth Advisors LLC lifted its holdings in Eli Lilly and Company (NYSE:LLY) by 43.6% in the 4th quarter, Holdings Channel reports. The firm owned 734 shares of the company’s stock after buying an additional 223 shares during the quarter. Octavia Wealth Advisors LLC’s holdings in Eli Lilly and Company were worth $428,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of the business. Thompson Investment Management Inc. bought a new position in Eli Lilly and Company in the 3rd quarter worth $27,000. Retirement Group LLC raised its holdings in Eli Lilly and Company by 159.1% in the 2nd quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after acquiring an additional 35 shares during the period. Cornerstone Planning Group LLC bought a new position in Eli Lilly and Company in the 2nd quarter worth $33,000. Legacy Financial Group LLC bought a new position in Eli Lilly and Company in the 3rd quarter worth $35,000. Finally, Optiver Holding B.V. bought a new position in Eli Lilly and Company in the 3rd quarter worth $36,000. Institutional investors and hedge funds own 82.53% of the company’s stock.

Insiders Place Their Bets

In other Eli Lilly and Company news, major shareholder Lilly Endowment Inc sold 54,032 shares of the company’s stock in a transaction dated Monday, January 29th. The shares were sold at an average price of $645.07, for a total transaction of $34,854,422.24. Following the sale, the insider now directly owns 99,488,598 shares of the company’s stock, valued at $64,177,109,911.86. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.13% of the company’s stock.

Eli Lilly and Company Price Performance

Shares of Eli Lilly and Company stock opened at $746.56 on Wednesday. The company has a current ratio of 0.94, a quick ratio of 0.73 and a debt-to-equity ratio of 1.69. The stock has a market capitalization of $709.35 billion, a price-to-earnings ratio of 128.72, a P/E/G ratio of 1.64 and a beta of 0.34. Eli Lilly and Company has a 1-year low of $367.35 and a 1-year high of $800.78. The firm’s 50-day moving average price is $763.51 and its two-hundred day moving average price is $657.01.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings data on Tuesday, February 6th. The company reported $2.49 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.19. The firm had revenue of $9.35 billion for the quarter, compared to analysts’ expectations of $8.95 billion. Eli Lilly and Company had a net margin of 15.36% and a return on equity of 51.22%. The company’s quarterly revenue was up 28.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $2.09 earnings per share. On average, equities analysts predict that Eli Lilly and Company will post 12.52 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages recently commented on LLY. Barclays lifted their target price on shares of Eli Lilly and Company from $680.00 to $810.00 and gave the stock an “overweight” rating in a report on Wednesday, February 7th. BMO Capital Markets boosted their price objective on shares of Eli Lilly and Company from $710.00 to $865.00 and gave the stock an “outperform” rating in a report on Wednesday, February 7th. Morgan Stanley boosted their price objective on shares of Eli Lilly and Company from $805.00 to $950.00 and gave the stock an “overweight” rating in a report on Friday, February 16th. Erste Group Bank upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Wednesday, April 3rd. Finally, Cantor Fitzgerald restated an “overweight” rating and set a $815.00 price objective on shares of Eli Lilly and Company in a report on Monday. Three investment analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $728.05.

Eli Lilly and Company Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.